Cian Healthcare Ltd
Incorporated in 2003, Cian Healthcare Ltd is engaged in manufacturing and marketing of pharmaceutical products.[1]
- Market Cap ₹ 7.95 Cr.
- Current Price ₹ 3.18
- High / Low ₹ 26.5 / 2.97
- Stock P/E
- Book Value ₹ 15.8
- Dividend Yield 0.00 %
- ROCE 5.22 %
- ROE 0.43 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.20 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 27.1%
- Company has a low return on equity of -1.91% over last 3 years.
- Promoters have pledged 34.5% of their holding.
- Promoter holding has decreased over last 3 years: -43.8%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|
| 57 | 74 | 78 | 69 | 62 | 81 | |
| 50 | 62 | 74 | 56 | 51 | 71 | |
| Operating Profit | 7 | 12 | 4 | 13 | 10 | 9 |
| OPM % | 13% | 16% | 6% | 19% | 17% | 12% |
| 1 | 0 | 0 | 1 | 1 | -12 | |
| Interest | 7 | 8 | 7 | 6 | 6 | 8 |
| Depreciation | 4 | 3 | 4 | 5 | 5 | 8 |
| Profit before tax | -4 | 1 | -6 | 2 | 0 | -18 |
| Tax % | 7% | 91% | -8% | -2% | -400% | |
| -4 | 0 | -6 | 2 | 0 | -18 | |
| EPS in Rs | -1.62 | 0.02 | -2.21 | 0.81 | 0.10 | -7.20 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| TTM: | 27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 53% |
| TTM: | -8600% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -33% |
| 3 Years: | -48% |
| 1 Year: | -85% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 25 | 25 | 25 | 25 |
| Reserves | 35 | 35 | 30 | 32 | 33 | 14 |
| 73 | 71 | 63 | 61 | 56 | 54 | |
| 25 | 28 | 47 | 42 | 48 | 51 | |
| Total Liabilities | 157 | 157 | 166 | 160 | 161 | 144 |
| 39 | 37 | 50 | 45 | 39 | 37 | |
| CWIP | 25 | 26 | 13 | 14 | 15 | 15 |
| Investments | 5 | 5 | 5 | 5 | 5 | 5 |
| 87 | 90 | 98 | 97 | 102 | 88 | |
| Total Assets | 157 | 157 | 166 | 160 | 161 | 144 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| -7 | 6 | 9 | 5 | 12 | |
| -27 | 3 | 1 | 3 | -1 | |
| 36 | -10 | -11 | -7 | -10 | |
| Net Cash Flow | 1 | -1 | -1 | -0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Debtor Days | 128 | 94 | 125 | 140 | 121 |
| Inventory Days | 267 | 313 | 300 | 400 | 486 |
| Days Payable | 220 | 209 | 270 | 296 | 371 |
| Cash Conversion Cycle | 175 | 197 | 155 | 244 | 236 |
| Working Capital Days | 151 | 180 | 155 | 208 | 193 |
| ROCE % | 7% | 0% | 7% | 5% |
Documents
Announcements
-
Clarification Letter For Technical Error For Filing Form INC-22 With Respect To Change In Registered Office Of The Company With The MCA Portal.
17h - Technical error filing INC-22 for registered office change under CIRP
-
Reconciliation Of Share Capital Audit Report Under Regulation 76 Of SEBI (Depositories And Participants) Regulations, 2018.
17h - Reconciliation of share capital audit report for quarter ended March 31, 2025
-
Structured Digital Database (SDD) Compliance Certificate
18h - Structured Digital Database (SDD) compliance certificate for Quarter ended 31st March, 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
12 Apr - Certificate under Regulation 74(5) of SEBI (DP) Regulation, 2018 for quarter ended 31st March, 2025.
-
Disclosure Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares And Takeover) Regulations, 2011 For The Financial Year Ended 31St March 2025.
7 Apr - Yearly disclosure from promoters for FY 2025.
Business Overview:[1][2]
CHI is a fully integrated pharmaceutical company dealing in gynecology, hematinic, cardio-diabetic, orthopedic, pediatric, derma-cosmetic, antibiotic, CNS, vitamins & nutrient products.